



Valentina Nekljudova

Kontakt

Valentina Nekljudova

Publikationen (42)

Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marme F, Müller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm D, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial. *N Engl J Med* 2024

Denkert C, Schneeweiss A, Rey J, Karn T, Hattesoehl A, Weber K, Rachakonda S, Braun M, Huober J, Jank P, Sinn H, Zahm D, Felder B, Hanusch C, Tepy-Szymanski J, Marme F, Fehm T, Thomalla J, Sinn B, Stiewe T, Marczyk M, Blohmer J, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover D, Solbach C, Metzger-Filho O, Jackisch C, Geyer C, Fasching P, Pusztai L, Nekljudova V, Untch M, Loibl S. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. *Cell Rep Med* 2024; 5:101825.

Sinn B, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marme F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching P, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. *Breast Cancer Res* 2024; 26:138.

Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marme F, Müller V, Schneeweiss A, Sinn H, Fehm T, Schem C, Stickeler E, Fasching P, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials. *Clin Cancer Res* 2024

Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm D, Hanusch C, Solbach C, Heinrich G, Hartkopf A, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). *ESMO Open* 2024; 9:103009.

Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, Stötzer O, Fasching P, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn B, Nekljudova V, Loibl S, Denkert C. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer – a translational insight from the GeparX trial. *Clin Cancer Res* 2023

Schmidt M, Nitz U, Reimer T, Schmatloch S, Graf H, Just M, Stickeler E, Untch M, Runnebaum I, Belau A, Huober J, Jackisch C, Hofmann M, Krockner J, Nekljudova V, Loibl S, GBG/AGO-B, NOGGO/WSG study groups. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial. *Eur J Cancer* 2023; 194:113324.

Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, Tesch H, Hanusch C, Salat C, Rhiem K, Solbach C, Fasching P, Jackisch C, Reinisch M, Lederer B, Mehta K, Link T, Nekljudova V, Loibl S, Untch M. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. *NPJ Breast Cancer* 2023; 9:23.

Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübke K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. *Cancers (Basel)* 2022; 14

Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. *JAMA Oncol* 2022; 8:1010-1018.

Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. *Eur J Cancer* 2021

Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübbe K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. *Lancet Oncol* 2021; 22:1151-1161.

Marme F, Loibl S, Lederer B, Tesch H, Hanusch C, Denkert C, Rey J, Rhiem K, Link T, Nekljudova V, Jackisch C, Fasching P, Huober J, Blohmer J, Schneeweiss A, Michel L, Solbach C, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 153:203-212.

Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. *Eur J Cancer* 2021; 148:159-170.

Furlanetto J, Lederer B, Gerber B, Zahm D, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Couch F, Schmutzler R, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J, Lübbe K, Untch M, Salat C, Huober J, Klare P, Fasching P. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 145:44-52.

Hildebrandt G, Loibl S, Bekes I, Nekljudova V, Heil J, Reitsamer R, Kaiser J, Sedlmayer F, Zierhut D, Kühn T, Wolter K, Krug D, Potenberg J, Gerber B, Stachs A, Reimer T. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. *Int J Radiat Oncol Biol Phys* 2020; 107:683-693.

Werutsky G, Nekljudova V, Vladimirova V, Kühn T, Rhiem K, Huober J, Krug D, Link T, Schneeweiss A, Gerber B, Jackisch C, Tesch H, Denkert C, Seiler S, Blohmer J, Fasching P, Hanusch C, Untch M, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. *Eur J Cancer* 2020; 130:92-101.

Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. *Clin Cancer Res* 2020; 26:1896-1904.

Krug D, Huober J, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Hilfrich J, Heil J, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J, Costa S, Denkert C, Ditsch N, Gerber B, Hanusch C, Loibl S. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. *Ann Surg Oncol* 2019; 26:3892-3901.

Furlanetto J, Mehta K, Nekljudova V, Untch M, Thomssen C, Hanusch C, Lück H, Nitz U, Bauerfeind I, Gerber B, Fasching P, Huober J, Schneeweiss A, Möbus V, Lederer B, von Minckwitz G, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. *Breast Cancer* 2019; 26:826-834.

Untch M, Hackmann J, Blohmer J, Rhiem K, Schmitt W, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Hanusch C, Just M, Fasching P, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. *J Clin Oncol* 2019; 37:2226-2234.

Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. *Breast Cancer Res* 2019; 21:60.

Schneeweiss A, Ingold-Heppner B, Blohmer J, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, von Minckwitz G, Thomalla J, Jackisch C, Kast K, Möbus V, Tesch H, Hanusch C, Denkert C, Lübke K, Huober J, Klare P, Kümmel S, Untch M, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. *Eur J Cancer* 2018; 106:181-192.

Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. *J Clin Oncol* 2018; 36:2281-2287.

Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). *J Clin Oncol* 2018; 36:1308-1316.

Hahnen E, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Neidhardt G, Schem C, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P, Blohmer J, Jackisch C, Paepke S, Gerber B, Kümmel S, Schmutzler R. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. *JAMA Oncol* 2017; 3:1378-1385.

van Mackelenbergh M, Weber K, von Minckwitz G, Untch M, Schneeweiss A, Müller V, Kümmel S, Blohmer J, Fasching P, Huober J, Hanusch C, Jackisch C, Stickeler E, Marme F, Schem C, Karn T, Nekljudova V, Denkert C, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. *Breast Cancer Res Treat* 2017; 167:59-71.

Riethdorf S, Untch M, von Minckwitz G, Schem C, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Weber K, Nekljudova V, Loibl S, Müller V, Pantel K. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. *Clin Cancer Res* 2017; 23:5384-5393.

Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. *Int J Cancer* 2015; 137:2981-8.

von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). *Cancer* 2015; 121:3639-48.

Loibl S, Mehta K, Nekljudova V, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Kümmel S, Paepke S, Untch M, Lederer B, Jackisch C, von Minckwitz G. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. *Breast Cancer Res Treat* 2015; 152:377-87.

Fontanella C, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Huober J, Hilfrich J, Hanusch C, Lederer B, Gade S, Vanoppen M, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Loibl S. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. *Breast Cancer Res Treat* 2015; 150:127-39.

Loibl S, Fasching P, Andre F, Lindner J, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Pfitzner B, Huober J, Heinrichs C, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm D, Sinn P, Khandan F, Eidtmann H, Dohnal K, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. *J Clin Oncol* 2014; 32:3212-20.

von Minckwitz G, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching P, Sinn B, Engels K, Mehta K, Nekljudova V, Klare P, Eidtmann H, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer J, Jackisch C, Paepke S, Gerber B, Zahm D, Kümmel S, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol* 2014; 15:747-56.

Gerber B, Loibl S, Nekljudova V, Hauschild M, Huober J, Blohmer J, Kunz G, Jackisch C, Solbach C, Hanusch C, Kittel K, Schrader I, Eggemann H, Tesch H, Fasching P, Rezai M, Eidtmann H, von Minckwitz G, Untch M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). *Ann Surg Oncol* 2014; 21:2517-24.

Loibl S, Denkert C, Hilfrich J, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Nekljudova V, von Minckwitz G, Huober J, Kümmel S, Volz C, Mau C, Blohmer J, Costa S, Eidtmann H, Fasching P, Gerber B, Hanusch C, Jackisch C, Untch M. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. *Breast Cancer Res Treat* 2014; 144:153-62.

Hilvo M, Orešič M, Denkert C, von Minckwitz G, Huober J, Untch M, Sysi-Aho M, Seppänen-Laakso T, Nekljudova V, Hyötyläinen T, Gade S, Loibl S. Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. *Int J Cancer* 2013; 134:1725-33.

von Minckwitz G, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Lück H, Müller V, Kreienberg R, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel I, Elling D, Conrad B, Loibl S. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. *J Clin Oncol* 2013; 31:3531-9.

Huober J, Kümmel S, Mau C, Jackisch C, Khandan F, Costa S, Krabisch P, Loibl S, Nekljudova V, Untch M, Höb C, Gerber B, Fasching P, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer J, Tesch H, Minckwitz G. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). *Eur J Cancer* 2013; 49:2284-93.

von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012; 30:1796-804.

von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* 2012; 366:299-309.

Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *Lancet Oncol* 2012; 13:135-44.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch